NCT05931393View on ClinicalTrials.gov

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

December 31, 2028

Conditions
RCCRenal Cell Carcinoma
Interventions
DRUG

Cabozantinib 80 MG

cabozantinib 80mg daily

Trial Locations (1)

75390

RECRUITING

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER